The content on this site is intended for healthcare professionals only
Dr Randy Sweis speaks to ecancer about the phase Ib TROPHY-U-01 Cohort 7 study.
The study evaluates sacituzumab govitecan combined with enfortumab vedotin and the PD-1 inhibitor zimberelimab in patients with previously untreated metastatic urothelial cancer.
He highlights that among 18 efficacy-evaluable patients, the combination achieved an objective response rate of 83%, including three complete responses.
Treatment-related toxicities were manageable, with no evidence of additive toxicity beyond the expected profiles of the individual drugs.
Dr Sweis says that the findings support further investigation of this combination as a potential first-line treatment approach for metastatic urothelial cancer.
Bladder cancer updates from the first half of 2026
Part 4: Clinical decision making - Interpretation of next generation sequencing results
Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC
Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival
Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer
Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC
ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer
